Induction of apoptosis in human cancer cells by targeting mitochondria with gold nanoparticles by Mkandawire, M. M. et al.
 
 
 
 
 
Dieses Dokument ist eine Zweitveröffentlichung (Verlagsversion) / 
This is a self-archiving document (published version):  
 
 
 
 
 
 
 
 
 
 
Diese Version ist verfügbar / This version is available on:  
https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-363316 
 
 
 
„Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFGgeförderten) Allianz- bzw. 
Nationallizenz frei zugänglich.“ 
 
This publication is openly accessible with the permission of the copyright owner. The permission is 
granted within a nationwide license, supported by the German Research Foundation (abbr. in German 
DFG). 
www.nationallizenzen.de/ 
 
 
 
M. M. Mkandawire, M. Lakatos, A. Springer, A. Clemens, D. Appelhans, U. Krause-
Buchholz, W. Pompe, G. Rödel, M. Mkandawire 
Induction of apoptosis in human cancer cells by targeting 
mitochondria with gold nanoparticles  
Erstveröffentlichung in / First published in: 
Nanoscale. 2015, 7(24), S. 10634–10640 [Zugriff am: 04.11.2019]. Royal Society of Chemistry.      
ISSN 2040-3372.  
DOI: https://doi.org/10.1039/c5nr01483b 
 
Nanoscale
PAPER
Cite this: Nanoscale, 2015, 7, 10634
Received 6th March 2015,
Accepted 9th May 2015
DOI: 10.1039/c5nr01483b
www.rsc.org/nanoscale
Induction of apoptosis in human cancer cells by
targeting mitochondria with gold nanoparticles†
M. M. Mkandawire,*a,b,c M. Lakatos,c A. Springer,c A. Clemens,b D. Appelhans,d
U. Krause-Buchholz,b W. Pompe,b G. Rödelb and M. Mkandawirec,e
A major challenge in designing cancer therapies is the induction of cancer cell apoptosis, although acti-
vation of intrinsic apoptotic pathways by targeting gold nanoparticles to mitochondria is promising. We
report an in vitro procedure targeting mitochondria with conjugated gold nanoparticles and investigating
eﬀects on apoptosis induction in the human breast cancer cell line Jimt-1. Gold nanoparticles were con-
jugated to a variant of turbo green ﬂuorescent protein (mitoTGFP) harbouring an amino-terminal mito-
chondrial localization signal. Au nanoparticle conjugates were further complexed with cationic
maltotriose-modiﬁed poly(propylene imine) third generation dendrimers. Fluorescence and transmission
electron microscopy revealed that Au nanoparticle conjugates were directed to mitochondria upon trans-
fection, causing partial rupture of the outer mitochondrial membrane, triggering cell death. The ability to
target Au nanoparticles into mitochondria of breast cancer cells and induce apoptosis reveals an alterna-
tive application of Au nanoparticles in photothermal therapy of cancer.
Introduction
One of the mechanisms for therapeutic destruction of cancer
cells is to induce apoptosis either extrinsically by targeting cell
surface receptors, or intrinsically via mitochondria.1 In the
extrinsic route, activated cell death receptors lead to activation
of caspase 8, which results in a caspase-signalling cascade. In
the mitochondria-mediated pathway, the formation of a multi-
meric Apaf-1/cytochrome c complex initiates activation of pro-
caspase 9, which cleaves and triggers downstream caspases 3,
6, and 7.2 Consequently, mitochondria are an attractive target
for the design of eﬀective, and specific cancer therapeutics
resulting in less collateral damage to the surrounding non-can-
cerous cells.3,4 A current strategy being investigated is exploit-
ing the photothermal eﬀect of gold nanoparticles (AuNPs) in
the presence of low energy sources to induce extrinsic or mito-
chondrial-mediated apoptosis.5–8
AuNPs have shown immense potential for cancer diagnosis
and therapy based on their surface plasmon resonance (SPR)
enhanced light scattering and absorption.9,10 AuNPs eﬃciently
convert the absorbed light into localized heat, which can be
exploited for selective laser photothermal therapies for
cancer.5,6 Additionally, conjugation of AuNPs to ligands
specifically targeting biomarkers on cancer cells allows
imaging and detection as well as photothermal treatment.6,7,11
Several studies have documented intracellular delivery and
internalization of AuNPs including their incorporation into
mitochondria to induce apoptosis.3,8,12 However, targeting
intracellular organelles in living cells remains a challenge due
to the aggregation behaviour of AuNPs and their ineﬃcient
release from endosomes.
To circumvent this problem, we explored the use of cationic
maltotriose-modified poly(propylene imine) (PPI) dendrimers
as transfection reagents of AuNPs into Jimt-1 cells. The result-
ing AuNP–protein and dendrimer complexes are considered
dendriplexes. Glycosylated dendrimers and hyper-branched
polymers possess high transfection eﬃciency and biocompati-
ble properties.13–15 For eﬃcient delivery to the target orga-
nelles, escape of polyplexes (complexes between oligo/
polynucleic acids and cationic polymeric materials)16 from the
endosomes is a prerequisite.4 The polyplexes are known to exit
endosomes via the “proton-sponge” mechanism.13 Further-
more, cationic open shell and neutral dense shell PPI glyco-
dendrimers can be used as transfection and stabilization
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agents for various particles17–19 and as biological agents to
interfere with fibril assemblies of prion peptides20 and pro-
teins.21 Other well-established cationic carrier systems such as
liposomes and the cell penetrating peptide protamines have
been shown to be unsuitable for transfection of green
diamond–antibody conjugates to the cytoplasm.16 However,
open and dense maltotriose shell PPI glycodendrimers possess
promisingly low or no toxicity under in vivo conditions.22
Motivated by the fact that this glycodendrimer has some
advantages for stabilizing and internalizing anionic hybrid
conjugates in comparison with other carrier systems, in this
study we also used the cationic 3rd generation PPI glycodendri-
mer with an open maltotriose shell (PPI-Mal-III G3)18 for trans-
fection of AuNP conjugates.
The aim of our study was to investigate selective targeting
of AuNPs to mitochondria of Jimt-1 cancer cells to initiate
apoptotic pathways. Jimt-1 cells are resistant to trastuzumab, a
cancer drug, which targets cell surface receptors to induce
apoptosis.23 To target AuNPs to mitochondria and to follow
their intracellular delivery, we conjugated AuNPs with a green
fluorescent protein harbouring the mitochondrial (mt) locali-
zation sequence of the inner membrane protein COX8 at its
amino terminus (mitoTGFP). In previous studies, the success-
ful delivery of ultra-small AuNPs (2.7 nm diameter) conjugated
to doxorubicin into the cell nuclei with DNA damage is the
likely cause of induced apoptosis.8 Another study demon-
strated that Au nanorods (length 55.6 ± 7.8 nm, width 13.3 ±
1.8 nm) could be intracellularly directed to mitochondria in
cancer cells, but not in mesenchymal cells, although the
uptake pathways in both cell types were similar.24
Results and discussion
Characteristics of AuNP conjugates
To explore the cellular uptake and intracellular traﬃcking of
the mitoTGFP–AuNP conjugates stabilized by glycodendrimer
PPI-Mal-III G3, we used citrate-stabilized AuNPs (20 nm) for
TEM visualization. AuNPs were synthesized according to Frens
et al.25 and characterized by TEM (ESI†) and UV-Vis spec-
troscopy (Fig. 1a). Conjugation of mitoTGFP to AuNPs is by non-
covalent binding of the protein to AuNPs at pH values close
to the isoelectric point of the protein, in the case of eGFP at
pH 5.5 as described previously.7,26 Bioconjugates were analysed
by optical changes in UV-Vis absorbance spectra due to the
plasmon resonance of AuNPs.7,27 Adsorption of PEG to AuNPs
showed a 6 nm red shift of the plasmon peak (Fig. 1). Upon con-
jugation of AuNPs to mitoTGFP and HAeGFP, a 12 nm red shift
was observed, denoting successful conjugation along with the
damping of the plasmon resonance band indicating molecule
attachment on the particle surface (Fig. 1). Variation in the red
shift is dependent on the diﬀerences in the dielectric nature of
the nanoparticle medium,28 as such, PEG-AuNPs show a much
smaller red shift than either mitoTGFP– or HAeGFP–AuNPs.
To confirm the conjugation, 40 µl of mitoTGFP–AuNP and
HAeGFP–AuNP conjugates were loaded on a 0.5% agarose gel
as described in the Experimental section. Migration towards
the cathode confirms the net negative charge of the conjugates
in TBE buﬀer (pH 8.0). The net negative charge originated
from the proteins mitoTGFP and HAeGFP with pI values of 5.8
and 5.9, respectively. Previous studies found the red shift of
AuNPs conjugated to ribonuclease S was dependent on the
size and the amount of adsorbate AuNPs.29
Transfection of AuNP conjugates
Conjugate uptake into cells requires a transfection reagent
such as sugar-decorated dendritic glycopolymers.13,14,17,30 In
this study, we used cationic PPI-Mal-III G3 to mediate transfec-
tion of anionic protein–AuNP complexes into Jimt-1 cells; to
demonstrate the eﬀectiveness of PPI-Mal-III G3 as a transfec-
tion reagent, mitoTGFP–AuNP conjugates were transfected
either in the presence or absence of dendrimers. One hour
after stopping transfection, cells were fixed and prepared for
TEM. No evidence of mitoTGFP–AuNPs inside the cells was
obtained in the absence of PPI-Mal-III G3 (Fig. 2(a)). In con-
trast, TEM micrographs of cells transfected with mitoTGFP–
AuNP conjugates in the presence of PPI-Mal-III G3 revealed
AuNPs as black spots inside cells (Fig. 2(b) and (c)), confirming
that PPI-Mal-III G3 can mediate transfection of AuNP conju-
gates. Receptor-mediated endocytosis is the most likely uptake
route of the dendrimer-protein–AuNP complex due to oligosac-
charide groups on the dendrimer AuNPs.13
Next, we investigated targeting of AuNP conjugates using
cells transfected with PEG–AuNPs, HAeGFP–AuNPs, and
mitoTGFP–AuNPs. After transfection, cells were incubated in
serum-containing medium for 24 h to permit targeting of
AuNP conjugates to intracellular organelles. TEM micrographs
of cells transfected with PEG–AuNPs showed AuNPs as black
Fig. 1 Absorption spectrum of 20 nm diameter AuNPs showing a 6 nm
red shift in the plasmon resonance peak upon conjugation of the AuNPs
to the polymer PEG, and a 12 nm red shift to the proteins. The insert
shows runs of 40 µl AuNP conjugates on 0.5% agarose gel at 10 kV per
cm to conﬁrm the conjugation. Lane 1 depicts AuNPs conjugated to
PEG; lane 2 depicts AuNPs conjugated to HAeGFP; and lane 3 is for
AuNPs conjugated to mitoTGFP. Due to the diﬀerences in electronega-
tivities of the proteins, mitoTGFP–AuNPs migrate faster than HAeGFP–
AuNPs.
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spots in endosomes (Fig. 3(a)) as they have previously been
reported31 and as we similarly found for HAeGFP–AuNPs
(Fig. 3(b)). Several studies have reported the uptake and intra-
cellular traﬃcking of protein-coated nanoparticles32,33 such as
ligand-conjugated quantum dots, which generally followed the
same uptake pathway as ligands, but with conjugates arrested
in endosomes.32 In our experiments, HAeGFP–AuNPs also
accumulated in endosomes and partly in lysosomes (Fig. 3(b))
suggesting an endo/lysosomal pathway. In contrast, transfec-
tions with mitoTGFP–AuNPs demonstrated that nanoparticles
are partially targeted to the inner mitochondrial membrane
(Fig. 3(c)). Previously, conjugation of organelle-specific target-
ing sequences to quantum dots resulted in delivery to either
the nucleus or mitochondria.34 The diﬀerent fates of AuNP
conjugates confirm the previous observations that surface
ligands play an important role in intracellular traﬃcking of
nanoparticles.35 We also observed diﬀerent uptake mech-
anisms (See ESI Fig. S1†), which are known to result in
diﬀerent downstream intracellular traﬃcking.36 An obvious
explanation would be that the dendrimers target the NPs to
mitochondria (the electronegative pole within a eukaryotic
cell) due to their cationic nature. However, our data on target-
ing of HA-eGFP do not support this view. Hence, we assume
that the dendrimer coatings of the MitoTGFP–AuNP conju-
gates are removed during intracellular traﬃcking, thus expos-
ing the mt targeting sequence of MitoTGFP–AuNPs.
MitoTGFP–AuNPs, transfected by PPI-Mal-III G3, enter the
cells, early endosomes, cytosol, and mitochondria, and they
are finally localized in the inner mitochondrial membrane
(Fig. 4) suggesting that at least some mitoTGFP–AuNPs evade
the lysosomal pathway. After uptake, mitoTGFP–AuNPs are
enclosed in early endosomes (Fig. 4(a)), which eventually
rupture, thereby releasing mitoTGFP–AuNPs to the cytosol
(Fig. 4(b)). Due to the mitochondrial-targeting signal,
mitoTGFP–AuNPs are directed to mitochondria and pass
through the outer mitochondrial membrane (OMM) (Fig. 4(c)).
Although how AuNP conjugates target mitochondria is not
clear, most likely cytosolic factors such as the mitochondrial
import stimulating factor (MSF) play an important role.37,38
MitoTGFP–AuNPs probably follow the uptake mechanism of
COX8, which is mediated by two translocase protein complexes
of the outer and inner mitochondrial membranes.39 However,
the size of the import pore (<2.6 nm) on inner and out mito-
chondrial membranes could block the entrance of larger nano-
particles40 although in our case, it is likely AuNP complexes
(∼20 nm) partially rupture the OMM upon entry (as seen in
TEM micrographs), where mitoTGFP–AuNPs co-localize with
the inner mt membrane (Fig. 4(c) and 3(c)).
Induction of apoptosis
As the entry of AuNPs into the inner mt membrane partially
ruptured the OMM (Fig. 4(c)), we hypothesized that the AuNP-
mediated rupture of OMM could trigger apoptosis via release
of cytochrome c, a protein resident in the intermembrane
space (IMS).4 Cytochrome c release could trigger a cascade of
caspases, eventually inducing cell death without additional
external stimuli. To confirm the apoptotic potential of
mitoTGFP–AuNPs, cells transfected with PEG–AuNPs,
HAeGFP–AuNPs and mitoTGFP–AuNPs were incubated with a
cell-permeable fluorogenic substrate for the apoptotic enzyme
caspase 3, which converts the substrate into a fluorescent dye.
Fig. 3 (a) TEM micrographs of breast cancer cells transfected with
PEG–AuNPs (20 nm). Black spots representing AuNPs were observed in
endosomes (see the arrow). (b) TEM micrograph of AuNPs in early endo-
somes (upper arrow) and lysosomes (lower arrow) in cells that were
transfected with AuNPs conjugated to HAeGFP. In (c) AuNPs conjugated
to mitoTGFP associate with mitochondria. Scale bars are 200 nm for (a),
and 1 µm for (b) and (c).
Fig. 2 (a) TEM micrographs of breast cancer cells incubated with
mitoTGFP–AuNPs in the absence of PPI-Mal-III G3 and (b) in the pres-
ence of the glycodendrimer. In both cases, cells were ﬁxed for 1 hour
after transfection was stopped. In (c) a magniﬁed TEM micrograph of the
part shown in (b) depicts AuNPs as black spots or clusters (see arrows)
inside the cells. Scale bars are 5 µm for (a) and (b) and 1 µm for (c).
Fig. 4 TEM micrographs of breast cancer cells transfected with
mitoTGFP–AuNPs in the presence of maltotriose-modiﬁed PPI dendri-
mers showing an intracellular traﬃcking pathway of mitoTGFP–AuNPs.
In (a) mitoTGFP–AuNPs are contained in an early endosome (EE); (b)
shows a ruptured early endosome with a few AuNPs contained in it and
some AuNPs released in the cytosol in close proximity to the endosome.
A possible site of membrane rupture is indicated by a white arrow; and,
in (c) mitoTGFP conjugated AuNPs (depicted as black spots) are shown
making their way into mitochondria. The entry of AuNPs is associated
with the rupture of the outer mitochondrial membrane (OMM) as shown
by the white arrow. The mitoTGFP conjugated AuNPs are associated
with the inner mitochondrial membrane (IMM). Scale bars are 200 nm
for (a), (b) and (c).
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Caspase activity is a critical step in the onset of apoptosis that
can be monitored using this fluorogenic substrate.41,42
Brightfield images documented healthy cells (Fig. 5(a)) with
no obvious signs of cell stress (i.e. cell shrinkage). Fluo-
rescence images of cells transfected with only the dendrimers
PPI-Mal-III G3 as a control (Fig. 5(a)–(c) show almost no fluo-
rescence, documenting the absence of caspase 3 activity
(Fig. 5(b)). Furthermore, dark spots indicating the presence of
nanoparticles were not detectable in brightfield images, as
anticipated (Fig. 5(a)) confirming the previous observations
that the glycosylated PPI dendrimers are non-cytotoxic.20
Brightfield images further revealed the presence of
imported AuNPs (seen as black spots) inside cells transfected
with PEG–AuNPs (Fig. 5(d)–(f )), HAeGFP–AuNPs (Fig. 5(g)–(i))
or mitoTGFP–AuNPs (Fig. 5( j)–(l)) in the presence of the cat-
ionic PPI glycodendrimer. Although bright-field images of
PEG–AuNP or HAeGFP–AuNP transfected cells appeared
healthy (Fig. 5(d) and (g)), fluorescence images reveal some
fluorescent spots (Fig. 5(e) and (h)) demonstrating the elevated
caspase activity indicative of an early stage of apoptosis.41
Cells transfected with mitoTGFP–AuNPs possess clear signs
of apoptosis including cell shrinkage and rounded cells,
clearly observable (Fig. 5( j))43,44 with diﬀuse high intensity
fluorescence in the cytoplasm indicating high caspase
activity39 and condensed chromatin confirming the pro-
gression of cell death (Fig. 5(l)).45 As seen in TEM images,
mitochondria of cells transfected with mitoTGFP–AuNP conju-
gates experienced outer mitochondria membrane rupture,
releasing the intermembrane cytochrome c to the cytosol, acti-
vating a caspase-signalling cascade, leading to programmed
cell death.4,46 Cells transfected with purified proteins did not
exhibit apoptotic symptoms (See ESI – Fig. S3†). Therefore,
transfection of mitochondrial localizing AuNP conjugates
could be regarded as apoptosis-inducing due to the mecha-
nical disruption of mitochondria, which in turn induces mito-
chondria-dependent apoptosis. The process is summarised
and illustrated in Scheme 1.
Experimental
Cell line, cell culture products, chemicals and reagents
Trisodium citrate and tetrachloroauric acid for synthesis of
AuNPs were purchased from Sigma Aldrich GmbH, Germany.
Synthesis and characterization of the third generation malto-
triose modified poly(propylene imine) (PPI) dendrimer
(PPI-Mal-III G3) have been described previously.18 We have
used the same charge of PPI-Mal-III G3 as in ref. 18. The struc-
ture of PPI-Mal-III G3 is presented in the ESI (Fig. S1†). The
plasmids encoding the mt localizing turbo green fluorescent
protein (mitoTGFP) and green fluorescent protein (GFP) were
purchased from Biocat GmbH, Germany. Cloning vectors
pet23b+ and E. coli strains Top 10F′ and BL21 DE3pLys were
from Novagen GmbH; restriction enzymes NheI and XhoI were
obtained from New England Biolabs GmbH, Germany.
Fig. 5 Brightﬁeld and ﬂuorescence images of the caspase 3 activity of
the transfected cells. Cells were transfected with dendrimers only (a–c),
PEG–AuNPs (d–f ), HAeGFP–AuNPs (g–i) and mitoTGFP–AuNPs ( j–l).
The ﬁgure shows brightﬁeld images (left column), caspase 3 staining
(middle column) and overlay images of brightﬁeld, nuclear, and caspase
3 activity staining (right column). All images were obtained under the
same conditions. The scale bar is 30 µm.
Scheme 1 Schematic presentation of the procedure involved in target-
ing of AuNPs to mitochondria as well as illustration of membrane
rupture that occurs once the nanoparticle enters the mitochondria.
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The human cancer line Jimt-1 was obtained from the
Deutsche Sammlung von Mikroorganismen und Zellkulturen
(DSMZ) GmbH, Germany. The cell line, derived from the
pleural eﬀusion of a 62-year-old woman with ductal breast
cancer after postoperative radiation in 2003, was reported to
carry an amplified HER-2 oncogene and to be insensitive to
HER-2-inhibiting drugs such as trastuzumab (Herceptin).47,48
Media and reagents for cell culture including Dulbeccos Modi-
fied Eagles Medium (DMEM) without phenol red, phosphate-
buﬀered saline, trypsin, and penicillin/streptomycin were from
PAA Laboratories GmbH, Germany. Microcell culture dishes
(35 mm diameter) for transfection were purchased from Ibidi
GmbH, Martinsried, Germany. The caspase 3 substrate
Phiphilux-G2D2 is a product of Oncoimmune Inc. and was
obtained from EMD Millipore, Germany.
Fixation, staining and resin embedding reagents for Trans-
mission Electron Microscopy (TEM) sample preparation
including glutaraldehyde, low melting agarose, uranyl acetate,
osmium tetraoxide, lead citrate, and modified Spurr embed-
ding kit were purchased from Serva Electrophoresis GmbH,
Germany, and copper grids from Plano GmbH, Germany.
Gold nanoparticles
Spherical AuNPs were prepared by citrate reduction according
to Frens et al.25 For the preparation of AuNPs with 20 nm dia-
meter, 2.5 ml of 1% trisodium citrate solution were added to
10 ml of 0.1% tetrachloroauric acid (HAuCl4·3H2O). The
mixture was stirred for 30 min at 70 °C until the colour
changed from colourless to ruby red. The resulting AuNPs
were characterized using a UV Vis spectrophotometer (Varian
Cary 100, Canterbury, Australia) and SEM-EDX (Leo 982 scan-
ning electron microscope, Carl Zeiss GmbH, Germany) (see
ESI – Fig. S2†). The formation of AuNPs can also be quantitat-
ively verified at the elemental level using XRD.
Expression of fluorescent proteins
The AuNPs used in the experiments were conjugated to
mitoTGFP or HAeGFP (haemagglutinin-tagged green fluo-
rescent protein). The genes encoding mitoTGFP and HAeGFP
were cloned, expressed and the respective proteins were puri-
fied. MitoTGFP was amplified by Polymerase Chain Reaction
(PCR) from a plasmid bearing the mitoTGFP gene using gene
specific primers with additional NheI/XhoI restriction sites.
Upon treatment with the respective enzymes, the PCR product
was cloned into the pET23b+ vector with an inherent histidine
tag and transformed into competent cells of Escherichia coli
strain TOP10F′. Plasmids isolated from positive clones were
confirmed by DNA sequencing and transformed into Escheri-
chia coli strain BL21 (DE3) pLysS for expression of mitoTGFP.
Transformants were grown at 30 °C in LB medium with ampi-
cillin and chloramphenicol to an absorbance OD600 of 0.5 fol-
lowed by a 4 hour induction with 0.5 mM IPTG. MitoTGFP was
purified under native conditions using nickel beads as
described previously.24 To check the mt targeting specificity of
mitoTGFP, an eGFP variant containing the viral haemaggluti-
nin tag instead of the mt targeting signal at its N terminus was
cloned, expressed and purified using the same procedure.
Conjugation of AuNPs to proteins
The concentration of AuNPs was calculated by Beer’s law using
the known molar extinction coeﬃcient of 20 nm AuNPs in
water (1.6 M−1 cm−1)25 with AuNP solution; the optical density
was measured by UV-Vis-spectroscopy. To conjugate AuNPs to
mitoTGFP, 100 µl of 0.1 nM AuNPs (20 nm diameter) were
incubated with 100 µl of mitoTGFP (0.05 µg µl−1 in PBS pH
5.5) for 15 min in the dark at room temperature. After incu-
bation, the samples were centrifuged at 7000g for 15 min. The
resulting conjugates were re-suspended in 100 µl PBS (pH 7.4).
Conjugation of AuNPs (0.1 nM) with HAeGFP was conducted
in an identical manner. To conjugate AuNPs to polyethylene
glycol, 100 µl AuNPs (0.1 nM) were mixed with 100 µl of 20%
(w/v) freshly prepared polyethylene glycol (PEG) 3350 dissolved
in water and incubated as per the protein–AuNP conjugates
with 100 µl of the conjugates pipetted into 96-well plates. The
localized surface Plasmon resonance (LSPR) shift in the absor-
bance spectrum was used to analyse AuNP conjugates with
confirmation by electrophoretic migration of 40 µl of AuNP
conjugate suspension in 0.5% agarose gel at 10 kV per cm in
TBE buﬀer (Tris-Borate-Ethylenediamine Tetraacetic Acid
(EDTA)) at pH 8.0.
Transfection and targeting AuNPs to mitochondria
Jimt-1 cells were grown in DMEM with 4500 g l−1 glucose, 10%
(v/v) fetal calf serum and 2 mM L-glutamine (PAA Laboratories
GmbH) without phenol red at 37 °C and 5% CO2. Cells were
routinely sub-cultured three times a week by enzymatic detach-
ment using trypsin.
For apoptosis assays, 3 × 105 cells were seeded in 35 mm
microcell culture dishes one day before transfection. Transfec-
tion complexes with mitoTGFP–AuNPs were constituted by
adding 100 µl of AuNP–protein conjugate suspension to 100 µl
HEPES buﬀer (pH 7.4). To this mixture, 100 µg of PPI-Mal-III
G3 were added and mixed thoroughly. Transfection complex
mixtures were incubated for 15 min at room temperature
before being transferred to the cell suspension. After incu-
bation for 4 h at 37 °C and 5% CO2 in the absence of serum,
transfection was stopped by washing the cells twice with PBS.
Thereafter, the incubation was continued for a further 24 h
with serum to allow targeting of AuNP conjugates to mitochon-
dria. Control treatments included mock transfection (incu-
bation with PPI-Mal-III G3 only) and non-transfected cells to
assess autofluorescence. Cells were analysed using fluo-
rescence and transmission electron microscopy to verify the
eﬃcacy of PPI-Mal-III G3 as a transfection reagent. To verify
apoptosis, transfected cells were incubated with 200 µl Phiphi-
luxG2D2 for 1 h followed by washing with 2 ml PBS.26,27
Validation of mitochondrial targeted AuNPs
Transmission Electron Microscopy (TEM) was used to assess if
AuNPs successfully targeted mitochondria. For TEM investi-
gations, 1 × 106 Jimt-1 cells were grown in 100 mm sterile Petri
Paper Nanoscale
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dishes. After transfection, the cells were detached using
trypsin and fixed with 2.5% glutaraldehyde in DMEM buﬀer at
37 °C and 5% CO2 for 24 h. The samples were then encapsu-
lated in 2% low melting agarose gel for 30 min at 4 °C. The
gel-encapsulated cells were sliced (about 1.5 × 1 mm) and fixed
with 1% osmium tetraoxide for 24 h, and then washed three
times for 15 min with distilled water. A series of 25%, 50%,
75%, 96% and 100% acetone/water mixtures (v/v) were used to
dehydrate samples over 4 h and then stained by 1% uranylace-
tate in acetone. The gel slices were stepwise embedded in
epoxy resin (30% for 4 h; 50% for 12 h; 70% for 4 h; 100% for
4 h; 100% for 12 h, and lastly 100% for 4 h). The resin was
stepwise polymerized at 50 °C for 3 h, and then at 55 °C–60 °C
over 72 h.28 Ultra-thin sections (50 nm) were prepared on a
Lexica Electron M Ultracut ultramicrotome, mounted on piolo-
form-coated copper grids and post-stained with uranylacetate
and lead citrate.29 Electron micrographs were obtained with a
scanning TEM at 30 kV or a Zeiss 912 Omega (Carl Zeiss
GmbH, Germany) at 120 kV. Furthermore, verification of cellu-
lar uptake can be done with complementary ICP-MS analysis.
The mitochondria are extracted from the whole cancer cells
and then the amount of Au is measured by ICP-MS.
Apoptosis verification
To confirm the apoptotic potential of mitoTGFP–AuNPs, cells
transfected with PEG–AuNPs, HAeGFP–AuNPs and mitoTGFP–
AuNPs were incubated with a cell-permeable fluorogenic sub-
strate for the apoptotic enzyme caspase 3, which converts the
substrate into a fluorescent dye. The CaspGLOW™ Fluorescein
Active Caspase-3 Staining Kit was used and the cells were
observed under a fluorescence microscope using an FITC
filter. Caspase positive cells appeared to have brighter green
signals, whereas caspase negative control cells show a much
weaker signal.
Conclusions
In this work, we successfully transfected AuNP conjugates
inside cells using cationic PPI glycodendrimers with open
maltotriose shells by targeting AuNPs conjugated to mitoTGFP.
Furthermore, the entry of AuNPs into mitochondria ruptured
the outer mitochondrial membrane, triggering apoptosis.
Transfection of mitochondrial localizing AuNP conjugates
induces apoptosis due to the mechanical disruption of mito-
chondria, which in turn induces mitochondria-dependent
apoptosis. This study provides a step towards development of
controlled and targeted induction of apoptosis in cancer cells,
which could provide an important tool in cancer therapy.
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